Mazdutide and Semaglutide Compared: How the Two Weight-Loss Drugs Differ
A look at how mazdutide and semaglutide differ in mechanism, trial results, and availability as weight-loss treatments.
Mazdutide and semaglutide have both attracted attention as injectable treatments for weight management, but they work in different ways and sit at different stages of clinical development. As interest in GLP-1 medications continues to grow, comparing the two drugs has become a frequent question for patients and clinicians.
How Each Drug Works
Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone that signals fullness, slows digestion, and helps regulate blood sugar. It is approved in major markets for type 2 diabetes and, at higher doses, for chronic weight management.
Mazdutide is a dual agonist that activates both GLP-1 and glucagon receptors. By engaging two hormonal pathways at once, it is designed to suppress appetite while also influencing energy expenditure, a combination that has drawn interest in obesity research.
Trial Results So Far
Semaglutide has an extensive evidence base. Large phase 3 trials showed average weight reductions of around 15% of body weight when the drug was combined with lifestyle changes, supporting its current place in clinical guidelines.
Mazdutide is at an earlier stage. Mid-stage studies reported in 2024 produced double-digit percentage weight loss over several months, but the drug has not yet completed the larger phase 3 trials regulators require before approval. Reported side effects for both drugs commonly include gastrointestinal symptoms such as nausea.
Availability and Practical Considerations
Semaglutide is widely prescribed under brand names including Wegovy and Ozempic, though supply and cost remain issues in many regions. Mazdutide is currently available only in China, where it was approved for diabetes in 2025, and is not yet authorised for weight management in the United States or Europe.
For anyone evaluating treatment options, the choice between established and investigational drugs can be significant, particularly given concerns about muscle loss during rapid weight reduction and the sustainability of any reduced-calorie eating plan used alongside medication.